UCLA-led researchers unveiled DUNP19, a radiotheranostic antibody targeting LRRC15 that detects, kills and reprograms aggressive, therapy‑resistant tumors including glioblastoma and osteosarcoma in preclinical models. The construct is designed for both imaging and targeted radiotherapy (theranostic), enabling patient selection and payload delivery in one agent. Separately, Full‑Life Technologies closed $77 million to advance a radiopharmaceutical and radionuclide‑drug conjugate portfolio and to build a Belgium GMP site. The financing underscores investor appetite for radionuclide platforms as academic radiotheranostics progress toward clinic and commercial manufacturing requirements accelerate.